Bares Capital Management Inc. Purchases Shares of 37,476 Medpace Holdings, Inc. $MEDP

Key Points

• Bares Capital Management Inc. acquired 37,476 shares of Medpace Holdings, valued at approximately $11.4 million, making it the firm's 10th biggest holding.
• Medpace reported $3.10 EPS for the last quarter, exceeding estimates, with revenue reaching $603.31 million, indicating a year-over-year increase of 14.2%.
• Analyst ratings on Medpace are mixed, with two buy ratings, nine holds, and three sells, as the average price target is set at $406.60.

Bares Capital Management Inc. bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 37,476 shares of the company's stock, valued at approximately $11,419,000. Medpace accounts for about 1.2% of Bares Capital Management Inc.'s investment portfolio, making the stock its 10th largest position. Bares Capital Management Inc. owned 0.13% of Medpace at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Mawer Investment Management Ltd. purchased a new position in shares of Medpace in the 1st quarter worth approximately $212,131,000. Vulcan Value Partners LLC grew its position in shares of Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company's stock worth $99,159,000 after buying an additional 224,578 shares during the last quarter. Fundsmith LLP purchased a new position in shares of Medpace in the 4th quarter worth approximately $42,372,000. Spyglass Capital Management LLC grew its position in shares of Medpace by 85.1% in the 4th quarter. Spyglass Capital Management LLC now owns 262,660 shares of the company's stock worth $87,264,000 after buying an additional 120,778 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company's stock worth $361,596,000 after buying an additional 102,015 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several research reports. Barclays lifted their price objective on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Cowen cut shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday, July 23rd. TD Cowen reiterated a "sell" rating and issued a $366.00 target price (up from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. Rothschild & Co Redburn lowered shares of Medpace from a "buy" rating to a "neutral" rating and boosted their price target for the stock from $342.00 to $474.00 in a report on Wednesday. Finally, Mizuho boosted their price target on shares of Medpace from $328.00 to $510.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $412.73.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of the stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares in the company, valued at $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Cornelius P. Mccarthy III sold 1,662 shares of the stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $465.04, for a total value of $772,896.48. Following the sale, the director directly owned 10,197 shares of the company's stock, valued at approximately $4,742,012.88. This represents a 14.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 161,266 shares of company stock valued at $74,111,427. 20.30% of the stock is owned by corporate insiders.

Medpace Stock Up 1.0%

Shares of Medpace stock traded up $4.64 during trading hours on Friday, reaching $486.98. 233,792 shares of the company's stock were exchanged, compared to its average volume of 316,283. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30. The company has a market capitalization of $13.68 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 3.06 and a beta of 1.44. The business has a fifty day moving average of $412.68 and a two-hundred day moving average of $344.19.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. Medpace's revenue for the quarter was up 14.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.